Symbolbild · KI-generiert
EyePoint, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
EyePoint Pharmaceuticals develops and markets medicines for the treatment of eye diseases, with a particular focus on drug delivery systems for the posterior segment of the eye. The company leverages its proprietary bioerodible technology to provide long-acting therapies for conditions such as diabetic macular oedema and non-infectious uveitis. EyePoint markets its own products and collaborates with pharmaceutical partners.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| EyePoint, Inc. | EYPT | NASDAQ | 1,03 Mrd. USD |
| Lexicon Pharmaceuticals, Inc. | LXRX | NASDAQ | 1,03 Mrd. USD |
| Alpha Tau Medical Ltd. | DRTS | NASDAQ | 1,04 Mrd. USD |
| Pacira BioSciences, Inc. | PCRX | NASDAQ | 1,04 Mrd. USD |
| Cullinan Therapeutics, Inc. | CGEM | NASDAQ | 1,01 Mrd. USD |
| Cronos Group Inc. | CRON | TSX | 1,04 Mrd. USD |
| Alto Neuroscience, Inc. | ANRO | NYSE | 1,05 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.